[{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"BELLUS Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"adMare BioInnovations \/ BELLUS Health","highestDevelopmentStatusID":"8","companyTruncated":"adMare BioInnovations \/ BELLUS Health"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Seyltx","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Seyltx","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Seyltx"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ AnGes","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ AnGes"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor is being investigated for the treatment of acute respiratory distress syndrome.

                          Product Name : AV-001

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 03, 2024

                          Lead Product(s) : Vasculotide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : AnGes

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : NP-120 (ifenprodil) is an NMDA receptor antagonist specifically targeting the NMDA type subunit 2B & it is a novel first-in-class treatment for idiopathic pulmonary fibrosis and its associated cough.

                          Product Name : NP-120

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 16, 2024

                          Lead Product(s) : Ifenprodil Tartrate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor is being investigated for the treatment of acute respiratory distress syndrome.

                          Product Name : AV-001

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 28, 2024

                          Lead Product(s) : Vasculotide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Seyltx gains access to Algernon’s NP-120 (ifenprodil), an N-methyl-D-aspartate receptor antagonist, which is a treating for idiopathic pulmonary fibrosis and associated cough.

                          Product Name : NP-120

                          Product Type : Other Small Molecule

                          Upfront Cash : $2.0 million

                          March 27, 2024

                          Lead Product(s) : Ifenprodil Tartrate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Seyltx

                          Deal Size : $2.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature.

                          Product Name : AV-001

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          November 14, 2023

                          Lead Product(s) : Vasculotide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : NP-120 (ifenprodil) selectively inhibits N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit. NMDA receptors are ion-channels found within the central and peripheral nervous system, including the area of the brain responsible for coordinati...

                          Product Name : NP-120

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 01, 2023

                          Lead Product(s) : Ifenprodil Tartrate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.

                          Product Name : BLU-5937

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 02, 2023

                          Lead Product(s) : Camlipixant

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.

                          Product Name : BLU-5937

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 10, 2022

                          Lead Product(s) : Camlipixant

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : NP-120 (ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and ne...

                          Product Name : NP-120

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2022

                          Lead Product(s) : Ifenprodil Tartrate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The Company will use the proceeds from the offering to fund research and development programs including NP-120 (ifenprodil), and for general and administrative expenses and for working capital purposes.

                          Product Name : NP-120

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 23, 2022

                          Lead Product(s) : Ifenprodil Tartrate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $1.4 million

                          Deal Type : Private Placement

                          blank